The Abbott infant formula lawsuit has resulted in a US jury awarding at least $53 million in damages over claims linked to necrotising enterocolitis in a premature infant. The case is part of broader litigation involving infant formula manufacturers, as courts examine safety concerns and medical evidence in neonatal nutrition.
Key Highlights
- Abbott infant formula lawsuit results in $53 million jury verdict in US NEC case
- Case links premature infant formula to serious intestinal condition necrotising enterocolitis
- Nearly 1,000 lawsuits filed against manufacturers over infant formula safety concerns
- Abbott reports about $40 billion annual revenue with modest growth in nutrition segment
Abbott infant formula lawsuit has led to a US jury awarding at least $53 million in damages over claims that a premature infant developed necrotising enterocolitis (NEC) after being fed the company’s formula.
The verdict was reported on April 10, 2026, following a trial that reviewed medical records and expert testimony.
Jurors found Abbott Laboratories liable and granted both compensatory and punitive damages. The company has denied the allegations and is expected to challenge the ruling through post-trial motions.
Inside the Courtroom
The Abbott infant formula lawsuit focused on whether cow’s milk-based formula increased the risk of NEC in premature infants.
NEC is a serious intestinal disease that can cause tissue damage and life-threatening complications.
Medical evidence cited in proceedings indicates that NEC has mortality rates exceeding 20% in severe cases.
The lawsuit argued that formula feeding may elevate risk compared with breast milk in vulnerable infants.
Mounting Legal Cases
The Abbott infant formula lawsuit is part of a wider legal trend in the United States.
Nearly 1,000 similar lawsuits have been filed against infant formula manufacturers, with many cases grouped in federal courts in Illinois.
Previous verdicts in related cases have varied, with some large jury awards currently under appeal. Courts continue to assess scientific evidence and product safety claims.
Industry and Financial Context
The Abbott infant formula lawsuit comes amid increased scrutiny of the infant nutrition sector.
Abbott reported annual revenue of about $40 billion in its latest financial results, with its nutrition segment contributing significantly.
In 2025, the company’s nutrition business recorded modest growth of around 1%, while US pediatric nutrition sales declined.
Global demand remains steady, particularly in Asia-Pacific markets, while developed regions face regulatory and legal pressures.
Abbott has maintained that its products meet safety standards and are supported by scientific research. The company states that NEC involves multiple risk factors, including prematurity.
FAQs
Q1. What is the Abbott infant formula lawsuit about?
It involves claims that Abbott’s formula increased the risk of NEC in a premature infant.
Q2. What is necrotising enterocolitis (NEC)?
NEC is a serious intestinal disease that affects premature babies and can be life-threatening.
Q3. How many similar lawsuits are there?
Nearly 1,000 cases have been filed in the United States involving infant formula-related claims.
Q4. Will Abbott pay the damages immediately?
The company is expected to challenge the verdict, so payment may depend on appeals or further rulings.
Follow Inspirepreneur Magazine for daily global business news.
